Results 201 to 210 of about 4,515 (264)

Cost-effectiveness analysis of the fixed-dose combination of Dorzolamide + Timolol versus Brinzolamide+Timolol in the treatment of ocular hypertension and Primary open-angle glaucoma in Vietnam

Y hoc Thanh pho Ho Chi Minh
Introduction: This pharmacoeconomic assessment aimed to explore the cost-effectiveness of the fixed-dose combination of Dorzolamide+Timolol (DTFC) in ocular hypertension and primary open-angle glaucoma (OH/POAG) in Vietnam.
Nguyen Thi Hong Tran, Hung Manh Nguyen, Uyen Le Lan Ngo, Chau Thi Khanh Le, N. T. Dang, N. Nguyen, Tuan Duc Nguyen, Yen Thi-hai Nguyen   +7 more
semanticscholar   +1 more source

Clinicians’ perspectives on the use of triple fixed-dose combination timolol + brinzolamide + brimonidine in glaucoma management in Indian settings

Journal of Ophthalmic Research and Practice
To assess the clinicians’ perspectives and preferences on the current glaucoma management among Indian clinicians, focusing on the triple fixed-dose combination (FDC) timolol + brinzolamide + brimonidine.
S. Manjula, M. K. Kumar
semanticscholar   +1 more source

Dorzolamide / timolol and brinzolamide / brimonidine fixed combination topical drug therapy tn the management of intraocular pressure in primary open angle glaucoma.

The Professional Medical Journal
Objective: To compare the mean change in intraocular pressure (IOP) achieved with dorzolamide/timolol versus brinzolamide/brimonidine fixed combination topical therapy in patients diagnosed with primary open-angle glaucoma (POAG).
Fauzan Ayub, Sidrah Latif, Hafsa Latif, S. Shah, Saman Ali, Muhammad Qasim Yazar   +5 more
semanticscholar   +1 more source

Brinzolamide/latanoprost

Reactions Weekly
openaire   +2 more sources

Revamping the corneal permeability and antiglaucoma therapeutic potential of brinzolamide using transniosomes: optimization, in vitro and preclinical evaluation.

Nanomedicine
Aim: This study aims to explore potential of transniosomes, a hybrid vesicular system, as ocular drug-delivery vehicle. Materials & methods: Thin-film hydration technique was used to fabricate brinzolamide-loaded transniosomes (BRZ-TN) and optimized ...
Rushikesh K. Patil, Vaibhavi Srivastava, Rohit Bhawale, K. P. Tryphena, D. Khatri, Nandkumar Doijad, N. Mehra   +6 more
semanticscholar   +1 more source

Brinzolamide/Timolol

Drugs & Aging, 2009
Brinzolamide 1%/timolol 0.5% fixed combination (brinzolamide/timolol) is a twice-daily eyedrops suspension comprising the carbonic anhydrase-II inhibitor brinzolamide and the beta-adrenergic receptor antagonist timolol. Brinzolamide/timolol produced clinically relevant reductions in mean intraocular pressure (IOP) from baseline and was more effective ...
Jamie D, Croxtall, Lesley J, Scott
openaire   +2 more sources

Preclinical Overview of Brinzolamide

Survey of Ophthalmology, 2000
The development of topically active carbonic anhydrase inhibitors (CAIs) is a significant recent achievement in glaucoma medical treatment. Brinzolamide, the newest topical CAI, exhibits selectivity, high affinity, and potent inhibitory activity for the carbonic anhydrase type II isozyme (CA-II), which is involved in aqueous humor secretion.
openaire   +2 more sources

Brimonidine/brinzolamide

Reactions Weekly
openaire   +2 more sources

A Simple Validated LC-UV Method for the Simultaneous Determination of Brimonidine and Brinzolamide in the Presence of Brinzolamide's Degradation Product (Major Metabolite) in Rabbit Aqueous Humor.

Journal of Chromatographic Science
A sensitive, specific, reliable and low-cost LC-UV method has been developed and validated for simultaneous quantification of brimonidine tartrate (BM) and brinzolamide (BZ) in rabbit aqueous humor (AH) in the presence of N-desethyl-brinzolamide (NDBZ ...
Marwa A Wahab Mubarak, M. A. Mohammad, Ramzia I El-Bagary, Ehab F. Elkady, N. F. Abo-Talib   +4 more
semanticscholar   +1 more source

Nanocarrier-based Drug Delivery of Brinzolamide for Ocular Diseases: A Mini-Review

Current Nanomedicine
Brinzolamide (BRZ) represents a significant advancement in glaucoma treatment as a topically active carbonic anhydrase inhibitor (CAI). It exhibits selectivity and potent inhibitory activity for carbonic anhydrase type II isozyme (CA-II), which is ...
Rashmi Maurya, Akash Vikal, Preeti Patel, R. Narang, B. Kurmi   +4 more
semanticscholar   +1 more source